story of the week
Efficacy and Safety of Palbociclib Plus Tamoxifen in Patients With HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
NPJ Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
NPJ Breast Cancer 2024 Aug 22;10(1)76, E Noguchi, T Yamanaka, H Mukai, N Yamamoto, CF Chung, YS Lu, DY Chang, J Sohn, GM Kim, KH Lee, SC Lee, T Iwasa, H Iwata, K Watanabe, KH Jung, Y Tanabe, SY Kang, H Yasojima, K Aogi, E Tokunaga, SH Sim, YS Yap, K Matsumoto, LM Tseng, Y Umeyama, K Sudo, Y Kojima, T Hata, A Kuchiba, T Shibata, K Nakamura, Y Fujiwara, K Tamura, K YonemoriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.